ImmunoTek Bio Centers
David Quint has a diverse work experience spanning several industries and roles. David is currently the Non-Executive Chairman at OrganaBio, LLC since June 2018. Prior to that, they co-founded and served as a Director at Quartz Properties, a residential real estate developer, starting in July 2017. David also co-founded and directed ImmunoTek Bio Centers, LLC, a developer of FDA Blood Establishments, starting in August 2013.
From April 1999 to December 2020, David Quint worked as the Managing Director and Partner at Bayview Asset Management, LLC. Additionally, they co-founded Bayview Italia, S.r.L. in June 2016 and served until November 2020.
In the earlier stages of their career, David Quint held various positions at Bayview Lending Group, Lehman Brothers, Citi, Security Pacific National Bank (SPNB), and SAIC. At Bayview Lending Group, they held the role of Chief Executive Officer and President/COO of Bayview Financial. At Lehman Brothers, they served as the Co-CEO of Aurora Loan Services and held roles as Sr Vice President - Trading and Vice President - Mortgage Research.
David Quint started their career as a Credit Analyst at Citi and later worked as an Associate in the Leveraged Finance Group at Security Pacific National Bank. David was also an Engineer at Pacifica Technology, which was acquired by SAIC.
Overall, David Quint has demonstrated a breadth of experience in executive leadership, real estate development, biomedical ventures, asset management, and finance.
David Quint received their Bachelor of Science (BS) degree in Physics from UC San Diego, where they studied from 1982 to 1986. Later, they pursued a Master of Business Administration (M.B.A.) degree with a focus on Finance at The Wharton School, from 1988 to 1990.
This person is not in any offices
ImmunoTek Bio Centers
1 followers
ImmunoTek Bio Centers LLC is the world's largest and fastest-growing independent plasma collection center operator. ImmunoTek is a global leader in developing a reliable plasma supply chain for international biotech companies and partnering with organizations for ancillary projects related to blood-plasma collection. Since its inception in 2013, ImmunoTek has built and operated more than 70 plasma collection centers, most of which have achieved or are in the process of attaining U.S. FDA licensure and European certification. ImmunoTek currently has centers operating in 20 states, with 20 additional centers under development and planning underway for more than 40 additional sites over the next three years.